Evidence map›Paper›PMID 41835396›Full record

ArticlebioRxiv : the preprint server for biology2026

Protein

Nithya Balasundaram, Ayşegül Erdem, Azeem Sharda, Veerle W Daniels, Phillip L Chea, Fleur Leguay, Youzhong Liu, Mark A Keibler, Charles Vidoudez, Andrew A Lane and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nithya BalasundaramCellular Metabolism and Microenvironment Laboratory, de Duve Institute, UCLouvain, Brussels, Belgium.
Ayşegül ErdemCellular Metabolism and Microenvironment Laboratory, de Duve Institute, UCLouvain, Brussels, Belgium.
Azeem ShardaDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Veerle W DanielsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Phillip L CheaDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Fleur LeguayCellular Metabolism and Microenvironment Laboratory, de Duve Institute, UCLouvain, Brussels, Belgium.
Youzhong LiuCellular Metabolism and Microenvironment Laboratory, de Duve Institute, UCLouvain, Brussels, Belgium.
Mark A KeiblerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Charles VidoudezHarvard Center for Mass Spectrometry, Harvard University, Cambridge, MA, USA.
Andrew A LaneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Didier VertommenMASSPROT platform, de Duve Institute, UCLouvain, Brussels, Belgium.
Hans CasteurImelda Hospital, Bonheiden, Belgium.
Michaël R LaurentImelda Hospital, Bonheiden, Belgium.
Sunia A TraugerHarvard Center for Mass Spectrometry, Harvard University, Cambridge, MA, USA.
Gregory StephanopoulosDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David T ScaddenDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0001-9821-7133
Nick van GastelCellular Metabolism and Microenvironment Laboratory, de Duve Institute, UCLouvain, Brussels, Belgium.ORCID 0000-0002-0563-3590

Funding

Hypoxia-induced Metabolic Changes in CancerR01CA160458 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ILIOPOULOS, OTHON, STEPHANOPOULOS, GREGORY · 2012 to 2016
$1.6M
Elucidating modulators of hepatic metabolism by quantitative flux analysisR01DK075850 · NIDDK · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI STEPHANOPOULOS, GREGORY · 2006 to 2010
$1.5M
NCI NIH HHS R01 CA160458NIDDK NIH HHS R01 DK075850
6 · The paper itself

Abstract

Though cancer cells' altered metabolism has been recognized for a century, the clinical success of metabolic targeting remains limited due to metabolic plasticity. Here, we use acute myeloid leukemia (AML) as a model to investigate this adaptability through combinatorial metabolic compound screening. Synthetic lethality emerged when AML cells were simultaneously treated with a glutaminase inhibitor and TOFA, a hypolipidemic agent. Sensitivity to this combination was also seen in primary patient samples and in other cancer types, while healthy hematopoietic progenitors were not affected. Unexpectedly, we discovered that TOFA acts through a non-canonical inhibition of protein

Identifiers

PMID41835396
PMCPMC12980385

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.